Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Study of PYX-106 in Solid Tumors
NCT05718557Phase 1Active, not recruiting
- Sponsor
- Pyxis Oncology
- Start
- May 2023
- Primary completion
- May 2026
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of pyx-106 in solid tumor (advanced stage), sponsored by Pyxis Oncology. Primary endpoints: Number of Participants Who Experience a Dose-Limiting Toxicity and Number of Participants Who Experience an Adverse Event. Started May 2023; status: active, not recruiting.
02
Drugs
pyx-106
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05718557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718557.